Fortress Biotech (STU:CNB1) Cyclically Adjusted PB Ratio: (As of Aug. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:CNB1 Fortress Biotech Inc STU:CNB1
46 GF Score
Price €1.93
GF Value €0.87
! 6 Warning Signs
View Full Analysis

What is Fortress Biotech Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Fortress Biotech  (STU:CNB1) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Fortress Biotech Cyclically Adjusted PB Ratio Related Terms


Fortress Biotech Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Fortress Biotech's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fortress Biotech Cyclically Adjusted PB Ratio Chart

Fortress Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.11 0.55 0.20 0.16 0.35

Fortress Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 0.33 0.35 0.27 0.30

STU:CNB1 vs PMN, VANI, SEER: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Fortress Biotech's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fortress Biotech Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fortress Biotech's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Fortress Biotech's Cyclically Adjusted PB Ratio falls into.


STU:CNB1
46GF Score
Fortress Biotech Inc STU:CNB1
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fortress Biotech Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Fortress Biotech's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Fortress Biotech's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=4.59/333.9520*333.9520
=4.590

Current CPI (Jun. 2026) = 333.9520.

Fortress Biotech Quarterly Data

Book Value per Share CPI Adj_Book
201609 10.017 241.428 13.856
201612 11.187 241.432 15.474
201703 13.306 243.801 18.226
201706 19.120 244.955 26.067
201709 9.192 246.819 12.437
201712 13.069 246.524 17.704
201803 9.618 249.554 12.871
201806 10.449 251.989 13.848
201809 8.641 252.439 11.431
201812 0.422 251.233 0.561
201903 4.378 254.202 5.751
201906 6.209 256.143 8.095
201909 4.995 256.759 6.497
201912 4.781 256.974 6.213
202003 6.432 258.115 8.322
202006 9.354 257.797 12.117
202009 13.191 260.280 16.925
202012 13.040 260.474 16.718
202103 13.719 264.877 17.297
202106 13.826 271.696 16.994
202109 11.967 274.310 14.569
202112 14.223 278.802 17.036
202203 12.536 287.504 14.561
202206 10.173 296.311 11.465
202209 8.630 296.808 9.710
202212 5.346 296.797 6.015
202303 4.060 301.836 4.492
202306 1.946 305.109 2.130
202309 1.748 307.789 1.897
202312 1.370 306.746 1.492
202403 1.093 312.332 1.169
202406 0.735 314.175 0.781
202409 0.691 315.301 0.732
202412 0.778 315.605 0.823
202503 0.696 319.799 0.727
202506 1.280 322.561 1.325
202509 1.535 324.800 1.578
202512 1.372 324.054 1.414
202603 4.520 330.213 4.571
202606 4.590 333.952 4.590

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Fortress Biotech (STU:CNB1) Overvalued in 2026?

Based on GuruFocus' analysis, Fortress Biotech stock appears to be overvalued. The current stock price of €1.93 is trading 121.8% above its estimated GF Value™ of €0.87.

Key valuation signals for STU:CNB1:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €0.87 vs. price of €1.93 (121.8% above fair value)
  • GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the STU:CNB1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Fortress Biotech Business Description

Address 1111 Kane Concourse, Suite 301, Bay Harbor Island, FL, USA, 33154
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.
46GF Score

Get the complete analysis for STU:CNB1

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.93
Price
€0.87
GF Value